Authors:
,
,
,
, and
T. Laskow
T. Laskow
Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD , USA
Search for other papers by T. Laskow in
Current site
Google Scholar
PubMed
Search for other papers by T. Laskow in
Current site
Google Scholar
PubMed
J. Langdon
J. Langdon
Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD , USA
Search for other papers by J. Langdon in
Current site
Google Scholar
PubMed
Search for other papers by J. Langdon in
Current site
Google Scholar
PubMed
P. Abadir
P. Abadir
Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD , USA
Search for other papers by P. Abadir in
Current site
Google Scholar
PubMed
Search for other papers by P. Abadir in
Current site
Google Scholar
PubMed
Q.-L. Xue
Q.-L. Xue
Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD , USA
Search for other papers by Q.-L. Xue in
Current site
Google Scholar
PubMed
Search for other papers by Q.-L. Xue in
Current site
Google Scholar
PubMed
J. Walston
jwalston@jhmi.edu
https://orcid.org/0000-0002-6965-2723
J. Walston
Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD , USA
Search for other papers by J. Walston in
Current site
Google Scholar
PubMed
Search for other papers by J. Walston in
Current site
Google Scholar
PubMed
Abstract
Background
Chronic inflammation (CI) is a common trait of aging associated with adverse outcomes including mortality. We hypothesized that recombinant human Lactoferrin (rhLf) would reduce chronic inflammation of aging.
Methods
Thirty-six community dwelling older adults were randomly assigned to rhLf or placebo treatment in 1:1 ratio for 3 months. IL-6, sTNFR1, Comprehensive Metabolic Panel (CMP), and Complete Blood Count (CBC) were measured at baseline, 1 month, 3 months, and 6 months. Physical and cognitive measures were completed at same timepoints, including 4-m walking speed (m/s), grip strength (kg), 6-min walking distance (m), home activity measured by accelerometer, trail making test – Part A (s) and – Part B (s), and Digit symbol substitution test (number correctly coded). Primary outcomes were differences in IL-6 and sTNFR1 concentrations evaluated by generalized linear model with log-link and gamma family distribution, controlling for baseline cytokine concentrations.
Results
rhLF was well-tolerated. There were a significant number of abdominal complaints and increased drop-out rate in placebo group. Participants in rhLf arm had non-significant lower mean percent increase in IL6 at 3 months (rhLf mean IL-6 6% lower than control, P = 0.843), and sTNFaR1 (rhLf mean 2% lower than control, P = 0.36). No significant changes were observed for the cognitive or physical measures.
Conclusion
Treatment with rhLf did not significantly alter serum IL6 or sTNFR1 concentrations of older adults. This study may have been underpowered to detect difference, but provided evidence that a larger sample-size could more definitively determine the effect of rhLF on age-associated CI.
Supplementary Materials
- Supplemental Materials
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Peters A, Delhey K, Nakagawa S, Aulsebrook A, Verhulst S. Immunosenescence in wild animals: meta‐analysis and outlook. Ecol Lett 2019; 22: 1709–22. https://doi.org/10.1111/ele.13343.
-
2.
Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014; 69: S4–S9. https://doi.org/10.1093/gerona/glu057.
-
3.
Sanada F, Taniyama Y, Muratsu J, Otsu R, Shimizu H, Rakugi H, et al. Source of chronic inflammation in aging. Front Cardiovasc Med 2018; 5: 12. https://doi.org/10.3389/fcvm.2018.00012.
-
4.
Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018; 15: 505–22. https://doi.org/10.1038/s41569-018-0064-2.
-
5.
Smith AJP, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009; 20: 43–59. https://doi.org/10.1016/j.cytogfr.2008.11.006.
-
6.
Dai L, Liu D, Guo H, Wang Y, Bai Y. Association between polymorphism in the promoter region of Interleukin 6 (-174 G/C) and risk of Alzheimer’s disease: a meta-analysis. J Neurol 2011; 259: 414–19. https://doi.org/10.1007/s00415-011-6164-0.
-
7.
Jurk D, Wilson C, Passos JF, Oakley F, Correia-Melo C, Greaves L, et al. Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat Commun 2014; 5: 4172. https://doi.org/10.1038/ncomms5172.
-
8.
Jo E, Lee S-R, Park B-S, Kim J-S. Potential mechanisms underlying the role of chronic inflammation in age-related muscle wasting. Aging Clin Exp Res 2012; 24: 412–22. https://doi.org/10.3275/8464.
-
9.
Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 2013; 15: 978–90. https://doi.org/10.1038/ncb2784.
-
10.
VanderVeen BN, Fix DK, Carson JA. Disrupted skeletal muscle mitochondrial dynamics, mitophagy, and biogenesis during cancer cachexia: a role for inflammation. Oxid Med Cell Longev 2017; 2017: 3292087. https://doi.org/10.1155/2017/3292087.
-
11.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119–31. https://doi.org/10.1056/nejmoa1707914.
-
12.
Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019; 380: 752–62. https://doi.org/10.1056/nejmoa1809798.
-
13.
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation 2003; 107: 3133–40. https://doi.org/10.1161/01.cir.0000077913.60364.d2.
-
14.
Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure. Circulation 2004; 109: 1594–602. https://doi.org/10.1161/01.cir.0000124490.27666.b2.
-
15.
Pahor M, Anton SD, Beavers DP, Cauley JA, Fielding RA, Kritchevsky SB, et al. Effect of losartan and fish oil on plasma IL-6 and mobility in older persons. The ENRGISE pilot randomized clinical trial. J Gerontol A Biol Sci Med Sci 2018; 74: 1612–19. https://doi.org/10.1093/gerona/gly277.
-
16.
Cooper C, Chapurlat R, Al-Daghri N, Herrero-Beaumont G, Bruyère O, Rannou F, et al. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say? Drugs Aging 2019; 36: 15–24. https://doi.org/10.1007/s40266-019-00660-1.
-
17.
Moore SA, Anderson BF, Groom CR, Haridas M, Baker EN. Three-dimensional structure of diferric bovine lactoferrin at 2.8 Å resolution. J Mol Biol 1997; 274: 222–36. https://doi.org/10.1006/jmbi.1997.1386.
-
18.
Rosa L, Cutone A, Lepanto M, Paesano R, Valenti P. Lactoferrin: a natural glycoprotein involved in iron and inflammatory homeostasis. Int J Mol Sci 2017; 18: 1985–85. https://doi.org/10.3390/ijms18091985.
-
19.
Pammi M, Suresh G. Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2017; CD007137. https://doi.org/10.1002/14651858.cd007137.pub5.
-
20.
Lepanto MS, Rosa L, Cutone A, Conte MP, Paesano R, Valenti P. Efficacy of lactoferrin oral administration in the treatment of anemia and anemia of inflammation in pregnant and non-pregnant women: an interventional study. Front Immunol 2018; 9: 2123. https://doi.org/10.3389/fimmu.2018.02123.
-
21.
Laffan AM, McKenzie R, Forti J, Conklin D, Marcinko R, Shrestha R, et al. Lactoferrin for the prevention of post-antibiotic diarrhoea. J Health Popul Nutr 2012; 29: 547–51. https://doi.org/10.3329/jhpn.v29i6.9889.
-
22.
Bharadwaj S, Naidu TAG, Betageri GV, Prasadarao NV, Naidu AS. Inflammatory responses improve with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal women. Inflamm Res 2010; 59: 971–8. https://doi.org/10.1007/s00011-010-0211-7.
-
23.
Schrack JA, Kuo P-L, Wanigatunga AA, Di J, Simonsick EM, Spira AP, et al. Active-to-Sedentary behavior transitions, fatigability, and physical functioning in older adults. J Gerontol A Biol Sci Med Sci 2018; 74: 560–7. https://doi.org/10.1093/gerona/gly243.
-
24.
Navarro SL, Brasky TM, Schwarz Y, Song X, Wang CY, Kristal AR, et al. Reliability of serum biomarkers of inflammation from repeated measures in healthy individuals. Cancer Epidemiol Biomarkers Prev 2012; 21: 1167–70. https://doi.org/10.1158/1055-9965.epi-12-0110.
-
25.
Cesari M, Penninx BWJH, Pahor M, Lauretani F, Corsi AM, Williams GR, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 2004; 59: M242–8. https://doi.org/10.1093/gerona/59.3.m242.
-
26.
Hsu FC, Kritchevsky SB, Liu Y, Kanaya A, Newman AB, Perry SE, et al. Association between inflammatory components and physical function in the health, aging, and Body composition study: a principal component analysis approach. J Gerontol A Biol Sci Med Sci 2009; 64A: 581–9. https://doi.org/10.1093/gerona/glp005.
-
27.
Palta P, Xue Q-L, Deal JA, Fried LP, Walston JD, Carlson MC. Interleukin-6 and C-reactive protein levels and 9-year cognitive decline in community-dwelling older women: the women’s health and aging study II. J Gerontol A Biol Sci Med Sci 2014; 70: 873–8. https://doi.org/10.1093/gerona/glu132.
-
28.
Newman AB, Sanders JL, Kizer JR, Boudreau RM, Odden MC, Zeki Al Hazzouri A, et al. Trajectories of function and biomarkers with age: the CHS all stars study. Int J Epidemiol 2016; dyw092–dyw92. https://doi.org/10.1093/ije/dyw092.
Editor-in-Chief
László ROSIVALL (Semmelweis University, Budapest, Hungary)
Managing Editor
Anna BERHIDI (Semmelweis University, Budapest, Hungary)
Co-Editors
- Gábor SZÉNÁSI (Semmelweis University, Budapest, Hungary)
- Ákos KOLLER (Semmelweis University, Budapest, Hungary)
- Zsolt RADÁK (University of Physical Education, Budapest, Hungary)
- László LÉNÁRD (University of Pécs, Hungary)
- Zoltán UNGVÁRI (Semmelweis University, Budapest, Hungary)
Assistant Editors
- Gabriella DÖRNYEI (Semmelweis University, Budapest, Hungary)
- Zsuzsanna MIKLÓS (Semmelweis University, Budapest, Hungary)
- György NÁDASY (Semmelweis University, Budapest, Hungary)
Hungarian Editorial Board
- György BENEDEK (University of Szeged, Hungary)
- Zoltán BENYÓ (Semmelweis University, Budapest, Hungary)
- Mihály BOROS (University of Szeged, Hungary)
- László CSERNOCH (University of Debrecen, Hungary)
- Magdolna DANK (Semmelweis University, Budapest, Hungary)
- László DÉTÁRI (Eötvös Loránd University, Budapest, Hungary)
- Zoltán GIRICZ (Semmelweis University, Budapest, Hungary and Pharmahungary Group, Szeged, Hungary)
- Zoltán HANTOS (Semmelweis University, Budapest and University of Szeged, Hungary)
- Zoltán HEROLD (Semmelweis University, Budapest, Hungary)
- László HUNYADI (Semmelweis University, Budapest, Hungary)
- Gábor JANCSÓ (University of Pécs, Hungary)
- Zoltán KARÁDI (University of Pecs, Hungary)
- Miklós PALKOVITS (Semmelweis University, Budapest, Hungary)
- Gyula PAPP (University of Szeged, Hungary)
- Gábor PAVLIK (University of Physical Education, Budapest, Hungary)
- András SPÄT (Semmelweis University, Budapest, Hungary)
- Gyula SZABÓ (University of Szeged, Hungary)
- Zoltán SZELÉNYI (University of Pécs, Hungary)
- Lajos SZOLLÁR (Semmelweis University, Budapest, Hungary)
- József TOLDI (MTA-SZTE Neuroscience Research Group and University of Szeged, Hungary)
- Árpád TÓSAKI (University of Debrecen, Hungary)
International Editorial Board
- Dragan DJURIC (University of Belgrade, Serbia)
- Christopher H. FRY (University of Bristol, UK)
- Stephen E. GREENWALD (Blizard Institute, Barts and Queen Mary University of London, UK)
- Tibor HORTOBÁGYI (University of Groningen, Netherlands)
- George KUNOS (National Institutes of Health, Bethesda, USA)
- Massoud MAHMOUDIAN (Iran University of Medical Sciences, Tehran, Iran)
- Tadaaki MANO (Gifu University of Medical Science, Japan)
- Luis Gabriel NAVAR (Tulane University School of Medicine, New Orleans, USA)
- Hitoo NISHINO (Nagoya City University, Japan)
- Ole H. PETERSEN (Cardiff University, UK)
- Ulrich POHL (German Centre for Cardiovascular Research and Ludwig-Maximilians-University, Planegg, Germany)
- Andrej A. ROMANOVSKY (University of Arizona, USA)
- Anwar Ali SIDDIQUI (Aga Khan University, Karachi, Pakistan)
- Csaba SZABÓ (University of Fribourg, Switzerland)
- Eric VICAUT (Université de Paris, UMRS 942 INSERM, France)
Editorial Correspondence:
Physiology International
Semmelweis University
Faculty of Medicine, Institute of Translational Medicine
Nagyvárad tér 4, H-1089 Budapest, Hungary
Phone/Fax: +36-1-2100-100
E-mail: pi@semmelweis.hu
Indexing and Abstracting Services:
- Biological Abstracts
- BIOSIS Previews
- CAB Abstracts
- CABELLS Journalytics
- EMBASE/Excerpta Medica
- Global Health
- Index Copernicus
- Index Medicus
- Medline
- Referativnyi Zhurnal
- SCOPUS
- WoS - Science Citation Index Expanded
| 2024 | |
|---|---|
| Scopus | |
| CiteScore | |
| CiteScore rank | |
| SNIP | |
| Scimago | |
| SJR index | 0.356 |
| SJR Q rank | Q2 |
| 2023 | |
|---|---|
| Web of Science | |
| Journal Impact Factor | 2.2 |
| Rank by Impact Factor | Q3 (Physiology) |
| Journal Citation Indicator | 0.58 |
| Scopus | |
| CiteScore | 3.4 |
| CiteScore rank | Q2 (Physical Therapy, Sports Therapy and Rehabilitation) |
| SNIP | 0.508 |
| Scimago | |
| SJR index | 0.407 |
| SJR Q rank | Q2 |
| Physiology International | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | Effective from 1st Apr 2025: 600 EUR/article |
| Printed Color Illustrations | 40 EUR (or 10 000 HUF) + VAT / piece |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2025 | Online subsscription: 752 EUR / 828 USD Print + online subscription: 880 EUR / 968 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Physiology International | |
|---|---|
| Language | English |
| Size | B5 |
| Year of Foundation |
2006 (1950) |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Magyar Tudományos Akadémia |
| Founder's Address |
H-1051 Budapest, Hungary, Széchenyi István tér 9. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 2498-602X (Print) |
| ISSN | 2677-0164 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Nov 2024 | 87 | 0 | 0 |
| Dec 2024 | 62 | 0 | 0 |
| Jan 2025 | 87 | 0 | 0 |
| Feb 2025 | 79 | 0 | 0 |
| Mar 2025 | 132 | 0 | 0 |
| Apr 2025 | 39 | 0 | 0 |
| May 2025 | 37 | 1 | 2 |
Author:
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory